Leveraging 225Ac-pretargeted radioimmunotherapy for application in pancreatic ductal adenocarcinoma therapy

Conclusion: PRIT allows the specific delivery of highly cytotoxic payload to tumor site competing with the conventional directly labeled antibody conjugate but results in reduced dose to normal tissue and decreased hematotoxicity. This study confirms the clinical relevance of 225Ac-PRIT.

Source: Journal of Nuclear Medicine - May 23, 2018 Category: Nuclear Medicine Authors: Poty, S., Mandleywala, K., Carter, L., Abdel-Atti, D., Membreno, R., Scholz, W., Zeglis, B., Lewis, J. Tags: Preclinical Probes for Oncology II Source Type: research